Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07057427 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer

Name: Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer — clinical trial record (NCT07057427)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 3

SponsorHenan Cancer Hospital

Started2025-06-24

View on ClinicalTrials.gov ↗

Henan Cancer Hospital

107 trials monitored

See 2 trials at risk

Breast Cancer

5,180 trials monitored

See 256 trials at risk

The aim of this study is to evaluate the efficacy of nab-paclitaxel (on days 1 and 8 of a 21-day cycle) compared to the standard regimen of docetaxel plus carboplatin, both combined with trastuzumab and pertuzumab, as neoadjuvant therapies for HER2-positive breast cancer.

Trial Details

NCT Number	NCT07057427
Lead Sponsor	Henan Cancer Hospital
Conditions	Breast Cancer
Enrollment	812 participants
Start Date	2025-06-24
Primary Completion	2028-06-30 (estimated)
Study Completion	2029-06-30 (estimated)
Updated on ClinicalTrials.gov	2025-07-09